Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | HTT | P42858 | 2/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | MMP1 | P03956 | 1/20 | 0.30 |
| ▸ | MMP2 | P08253 | 1/20 | 0.30 |
| ▸ | MMP3 | P08254 | 1/20 | 0.30 |
| ▸ | MMP9 | P14780 | 1/20 | 0.30 |
| ▸ | MMP8 | P22894 | 1/20 | 0.30 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL636356 | 0.85 | KMT2A (0.39) | ALDH1A1KMT2APOLBNPSR1MMP1 | |
| SCHEMBL21393556 | 0.72 | ALDH1A1 (0.34) | ALDH1A1HTTPOLBNPSR1LMNA | |
| SCHEMBL12955348 | 0.70 | — | — | |
| Hydrochloric Acid SCHEMBL15795178 | 0.68 | KMT2A (0.37) | ALDH1A1KMT2AHTTMMP1MMP2 | |
| SCHEMBL51396 | 0.68 | NPSR1 (0.57) | ALDH1A1KMT2AHTTNPSR1PKM | |
| SCHEMBL12073745 | 0.67 | — | — | |
| SCHEMBL15200521 | 0.67 | — | — | |
| SCHEMBL18664186 | 0.67 | ALDH1A1 (0.36) | ALDH1A1KMT2AHTTPOLBMMP1 | |
| SCHEMBL18664185 | 0.67 | ALDH1A1 (0.36) | ALDH1A1KMT2AHTTMMP1MMP2 | |
| SCHEMBL13753969 | 0.67 | SPHK1 (0.45) | ALDH1A1KMT2AHTTMMP1MMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11078168-B2 | Substituted N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase | Phenex Discovery Verwaltungs-GmbH (DE) | 2021-08-03 | — | — | US | disclosed |
| US-20190292160-A1 | SUBSTITUTED N-HYDROXYAMIDINOHETEROCYCLES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | Phenex Discovery Verwaltungs-GmbH (DE) | 2019-09-26 | — | — | US | disclosed |
| US-8143305-B2 | 2,3-substituted indole derivatives for treating viral infections | SCHERING CORPORATION (US) | 2012-03-27 | — | — | US | disclosed |
| US-8143305-B2 | 2,3-substituted indole derivatives for treating viral infections | SCHERING CORPORATION (US) | 2012-03-27 | — | — | US | disclosed |
| US-20110033417-A1 | 2,3-SUBSTITUTED INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS | MERCK SHARP & DOHME CORP. | 2011-02-10 | — | — | US | disclosed |
| US-20110033417-A1 | 2,3-SUBSTITUTED INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS | MERCK SHARP & DOHME CORP. | 2011-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110033417-A1 | 2,3-SUBSTITUTED INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS | IDO2, IDO1, IRF3 | ALDH1A1 1792/4885KMT2A 321/4885HTT 747/4885 |
| US-11078168-B2 | Substituted N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase | IDO1, IDO2, INMT | ALDH1A1 650/4885KMT2A 654/4885HTT 87/4885 |
| US-20190292160-A1 | SUBSTITUTED N-HYDROXYAMIDINOHETEROCYCLES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | IDO1, IDO2, INMT | ALDH1A1 650/4885KMT2A 654/4885HTT 87/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.